NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
University of Pittsburgh
Bristol-Myers Squibb
Anaveon AG
SQZ Biotechnologies
AIO-Studien-gGmbH